Dibyajyoti Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dibyajyoti Das has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Kalyani Pathak
Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, Assam, India
4 shared publications - Aparoop Das
Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, Assam, India
3 shared publications - Riya Saikia
Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, India
3 shared publications - Abhishek Parasar
Pratiksha Institute of Pharmaceutical Sciences
2 shared publications Aparoop Das
2 shared publications- Ariful Islam
Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh, India
2 shared publications
Latest Publications
- 24 August 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26, 1-21
Artificial Intelligence in Medicinal Chemistry Decision-Making: From Virtual Screening to Lead Optimization
Artificial Intelligence (AI) is increasingly embedded within modern medicinal chemistry workflows, particularly across the Design–Make–Test–Analyse (DMTA) cycle, where critical decisions must be made under conditions of uncertainty. Rather than functioning as a stand-alone predictor, AI is best understood as a decision-support framework that assists chemists in selecting screening hits, prioritising analogues for synthesis, managing multi-parameter optimisation, and identifying developability and safety risks at early stages. This structured narrative review examines how contemporary Machine Learning (ML) and Deep Learning (DL) approaches are being applied at key decision points in small-molecule drug discovery, including virtual screening and hit triage, Structure-Activity Relationship (SAR) prioritisation, lead optimisation for Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) liabilities, and synthetic feasibility assessment through retrosynthesis planning. By integrating ligand-based and structure-based models, multi-task learning, active learning, generative design, and uncertainty-aware predictions, AI systems can reduce experimental burden while improving the quality of decisions made by medicinal chemists. However, the practical impact of these tools depends critically on appropriate validation strategies, applicability domain assessment, and probability calibration to avoid misleading confidence. Taken together, the evidence reviewed here supports models of AI-augmented medicinal chemistry, in which data-driven predictions and human chemical intuition jointly enable more efficient, transparent, and reliable progression from hits to optimised lead candidates.
- 24 August 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26, 1-21
Artificial Intelligence in Medicinal Chemistry Decision-Making: From Virtual Screening to Lead Optimization
Artificial Intelligence (AI) is increasingly embedded within modern medicinal chemistry workflows, particularly across the Design–Make–Test–Analyse (DMTA) cycle, where critical decisions must be made under conditions of uncertainty. Rather than functioning as a stand-alone predictor, AI is best understood as a decision-support framework that assists chemists in selecting screening hits, prioritising analogues for synthesis, managing multi-parameter optimisation, and identifying developability and safety risks at early stages. This structured narrative review examines how contemporary Machine Learning (ML) and Deep Learning (DL) approaches are being applied at key decision points in small-molecule drug discovery, including virtual screening and hit triage, Structure-Activity Relationship (SAR) prioritisation, lead optimisation for Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) liabilities, and synthetic feasibility assessment through retrosynthesis planning. By integrating ligand-based and structure-based models, multi-task learning, active learning, generative design, and uncertainty-aware predictions, AI systems can reduce experimental burden while improving the quality of decisions made by medicinal chemists. However, the practical impact of these tools depends critically on appropriate validation strategies, applicability domain assessment, and probability calibration to avoid misleading confidence. Taken together, the evidence reviewed here supports models of AI-augmented medicinal chemistry, in which data-driven predictions and human chemical intuition jointly enable more efficient, transparent, and reliable progression from hits to optimised lead candidates.
- 2 January 2026
- Published by Springer Nature
- p. 187-234
Chitosan in Food Packaging: Harnessing Crustacean Waste
- 2 January 2026
- Published by Springer Nature
- p. 187-234
Chitosan in Food Packaging: Harnessing Crustacean Waste
- Open Access
- 7 November 2025
- Published by MDPI AG in Biophysica
- Vol. 5 (4) , 52
Druggable Ensembles of Aβ and Tau: Intrinsically Disordered Proteins Biophysics, Liquid–Liquid Phase Separation and Multiscale Modeling for Alzheimer’s
Alzheimer’s disease is driven by multiple molecular drivers, including the pathological behavior of two intrinsically disordered proteins, amyloid-β (Aβ) and tau, whose aggregation is regulated by sequence-encoded ensembles and liquid–liquid phase separation (LLPS). This review integrates recent advances in biophysics, structural biology, and computational modeling to provide a multiscale perspective on how sequence determinants, post-translational modifications, and protein dynamics regulate the conformational landscapes of Aβ and tau. We discuss sequence-to-ensemble principles, from charge patterning and aromatic binders to familial mutations that reprogram structural ensembles and modulate LLPS. Structural studies, including NMR, SAXS, cryo-EM, and cryo-electron tomography, trace transitions from disordered monomers to fibrils and tissue-level structures. We highlight experimental challenges in LLPS assays, emerging standards for reproducibility, e.g., LLPSDB, PhaSePro, and FUS benchmarks, and computational strategies to refine and condensate modeling. Finally, we explore the therapeutic implications, including condensate-aware medicinal chemistry, ensemble-driven docking, and novel insights from clinical trials of anti-Aβ antibodies. Together, these perspectives underscore a paradigm shift toward environment- and ensemble-aware therapeutic design for Alzheimer’s and related protein condensation disorders.
- 7 November 2025
- Published by MDPI AG in Biophysica
- Vol. 5 (4) , 52
Open AccessDruggable Ensembles of Aβ and Tau: Intrinsically Disordered Proteins Biophysics, Liquid–Liquid Phase Separation and Multiscale Modeling for Alzheimer’s
Alzheimer’s disease is driven by multiple molecular drivers, including the pathological behavior of two intrinsically disordered proteins, amyloid-β (Aβ) and tau, whose aggregation is regulated by sequence-encoded ensembles and liquid–liquid phase separation (LLPS). This review integrates recent advances in biophysics, structural biology, and computational modeling to provide a multiscale perspective on how sequence determinants, post-translational modifications, and protein dynamics regulate the conformational landscapes of Aβ and tau. We discuss sequence-to-ensemble principles, from charge patterning and aromatic binders to familial mutations that reprogram structural ensembles and modulate LLPS. Structural studies, including NMR, SAXS, cryo-EM, and cryo-electron tomography, trace transitions from disordered monomers to fibrils and tissue-level structures. We highlight experimental challenges in LLPS assays, emerging standards for reproducibility, e.g., LLPSDB, PhaSePro, and FUS benchmarks, and computational strategies to refine and condensate modeling. Finally, we explore the therapeutic implications, including condensate-aware medicinal chemistry, ensemble-driven docking, and novel insights from clinical trials of anti-Aβ antibodies. Together, these perspectives underscore a paradigm shift toward environment- and ensemble-aware therapeutic design for Alzheimer’s and related protein condensation disorders.
- 19 August 2024
- Published by Wiley in Advanced Therapeutics
- Vol. 7 (10)
l‐Asparaginase Bio‐Betters: Insight Into Current Formulations, Optimization Strategies and Future Bioengineering Frontiers in Anti‐Cancer Drug Development
Cancer remains a persistent global health concern, representing a significant challenge in medical science and patient care. In this context, l‐asparaginase has emerged as a promising therapeutic agent due to its unique ability to deplete circulating asparagine, thereby selectively targeting cancer cells. However, despite its potential, current formulations of l‐asparaginase are not without limitations. Issues such as immunogenicity, short half‐life, and variable efficacy present hurdles in its widespread clinical application. To overcome these hurdles, researchers are focusing on developing bio‐better versions of l‐asparaginase. These bio‐betters aim to enhance stability, reduce immunogenicity, and optimize enzyme kinetics, thus improving treatment outcomes. This review critically assesses the current landscape of l‐asparaginase bio‐betters, offering insights into ongoing formulations and advancements, optimization strategies, and future bio‐engineering frontiers. It discusses modifications to enhance therapeutic properties and explores innovative approaches like in‐silico enzyme engineering and artificial intelligence, highlighting their potential to improve the therapeutic profile of l‐asparaginase. Challenges and debates surrounding the l‐asparaginase mechanism are also addressed. By addressing current challenges and outlining future directions, this review aims to contribute to the advancement of anti‐cancer therapeutics, particularly in the context of l‐asparaginase bio‐better research.
- 19 August 2024
- Published by Wiley in Advanced Therapeutics
- Vol. 7 (10)
l‐Asparaginase Bio‐Betters: Insight Into Current Formulations, Optimization Strategies and Future Bioengineering Frontiers in Anti‐Cancer Drug Development
Cancer remains a persistent global health concern, representing a significant challenge in medical science and patient care. In this context, l‐asparaginase has emerged as a promising therapeutic agent due to its unique ability to deplete circulating asparagine, thereby selectively targeting cancer cells. However, despite its potential, current formulations of l‐asparaginase are not without limitations. Issues such as immunogenicity, short half‐life, and variable efficacy present hurdles in its widespread clinical application. To overcome these hurdles, researchers are focusing on developing bio‐better versions of l‐asparaginase. These bio‐betters aim to enhance stability, reduce immunogenicity, and optimize enzyme kinetics, thus improving treatment outcomes. This review critically assesses the current landscape of l‐asparaginase bio‐betters, offering insights into ongoing formulations and advancements, optimization strategies, and future bio‐engineering frontiers. It discusses modifications to enhance therapeutic properties and explores innovative approaches like in‐silico enzyme engineering and artificial intelligence, highlighting their potential to improve the therapeutic profile of l‐asparaginase. Challenges and debates surrounding the l‐asparaginase mechanism are also addressed. By addressing current challenges and outlining future directions, this review aims to contribute to the advancement of anti‐cancer therapeutics, particularly in the context of l‐asparaginase bio‐better research.
- Open Access
- 28 July 2024
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 12
Exploring the therapeutic potential of xanthones in diabetes management: Current insights and future directions
- 28 July 2024
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 12
Open AccessExploring the therapeutic potential of xanthones in diabetes management: Current insights and future directions
- Open Access
- 12 June 2024
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 12
Nanohybrid cerasomes: Advancements in targeted drug and gene delivery
- 12 June 2024
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 12
Open AccessNanohybrid cerasomes: Advancements in targeted drug and gene delivery
- Open Access
- 29 December 2023
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 4 (6) , 1135-1167
3D printing in biomedicine: advancing personalized care through additive manufacturing
The integration of three-dimensional (3D) printing techniques into the domains of biomedical research and personalized medicine highlights the evolving paradigm shifts within contemporary healthcare. This technological advancement signifies potential breakthroughs in patient-specific therapeutic interventions and innovations. This systematic review offers a critical assessment of the existing literature, elucidating the present status, inherent challenges, and prospective avenues of 3D printing in augmenting biomedical applications and formulating tailored medical strategies. Based on an exhaustive literature analysis comprising empirical studies, case studies, and extensive reviews from the past decade, pivotal sectors including tissue engineering, prosthetic development, drug delivery systems, and customized medical apparatuses are delineated. The advent of 3D printing provides precision in the fabrication of patient-centric implants, bio-structures, and devices, thereby mitigating associated risks. Concurrently, it facilitates the ideation of individualized drug delivery paradigms to optimize therapeutic outcomes. Notwithstanding these advancements, issues concerning material biocompatibility, regulatory compliance, and the economic implications of avant-garde printing techniques persist. To fully harness the transformative potential of 3D printing in healthcare, collaborative endeavors amongst academicians, clinicians, industrial entities, and regulatory bodies are paramount. With continued research and innovation, 3D printing is poised to redefine the trajectories of biomedical science and patient-centric care. The paper aims to justify the research objective of whether to what extent the integration of 3D printing technology in biomedicine enhances patient-specific treatment and contributes to improved healthcare outcomes.
- 29 December 2023
- Published by Open Exploration Publishing in Exploration of Medicine
- Vol. 4 (6) , 1135-1167
Open Access3D printing in biomedicine: advancing personalized care through additive manufacturing
The integration of three-dimensional (3D) printing techniques into the domains of biomedical research and personalized medicine highlights the evolving paradigm shifts within contemporary healthcare. This technological advancement signifies potential breakthroughs in patient-specific therapeutic interventions and innovations. This systematic review offers a critical assessment of the existing literature, elucidating the present status, inherent challenges, and prospective avenues of 3D printing in augmenting biomedical applications and formulating tailored medical strategies. Based on an exhaustive literature analysis comprising empirical studies, case studies, and extensive reviews from the past decade, pivotal sectors including tissue engineering, prosthetic development, drug delivery systems, and customized medical apparatuses are delineated. The advent of 3D printing provides precision in the fabrication of patient-centric implants, bio-structures, and devices, thereby mitigating associated risks. Concurrently, it facilitates the ideation of individualized drug delivery paradigms to optimize therapeutic outcomes. Notwithstanding these advancements, issues concerning material biocompatibility, regulatory compliance, and the economic implications of avant-garde printing techniques persist. To fully harness the transformative potential of 3D printing in healthcare, collaborative endeavors amongst academicians, clinicians, industrial entities, and regulatory bodies are paramount. With continued research and innovation, 3D printing is poised to redefine the trajectories of biomedical science and patient-centric care. The paper aims to justify the research objective of whether to what extent the integration of 3D printing technology in biomedicine enhances patient-specific treatment and contributes to improved healthcare outcomes.